Oppenheimer analyst Kevin DeGeeter initiated coverage of Exact Sciences with an Outperform rating and $130 price target. The stock should "outpace the market" as Street estimates are updated to include Genomic Health (GHDX) and target merger synergies potentially exceed management's target of $25M in year three, DeGeeter tells investors in a research note. Further the analyst believes there could be upside to Exact Sciences' guidance for combined 2020 revenue of $1.6B and gross profit of $1.2B. He sees Genomic Health's franchise as positioned for sustained growth from potential introduction of in vitro diagnostic kits for markets outside the U.S.